Further action taken on COX 2 inhibitors in EuropeBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7507.12-a (Published 30 June 2005) Cite this as: BMJ 2005;331:12
- Caroline White
The European drugs watchdog, the European Medicines Agency, has recommended the continued suspension of the cyclo-oxygenase-2 inhibitor valdecoxib (Bextra), at the conclusion of its review on the safety of this class of drugs last week. The agency's Committee for Medicinal Products for Human Use also strengthened its guidance for prescribers and patients and urged the companies that market COX 2 inhibitors in Europe to carefully monitor and assess adverse reactions.
In its deliberations, the committee agreed that the data for the other drugs in the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial